Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.62 |
| ▸ | FAAH | O00519 | 5/20 | 0.56 |
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5389334 | 1.00 | CA2 (0.62) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL18643527 | 1.00 | CA2 (0.62) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL5383600 | 1.00 | CA2 (0.62) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL8957776 | 1.00 | CA2 (0.62) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL8778782 | 1.00 | CA2 (0.62) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL8778820 | 1.00 | CA2 (0.62) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL7739945 | 1.00 | CA2 (0.62) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL8778722 | 1.00 | CA2 (0.62) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL8778834 | 1.00 | CA2 (0.62) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL8485736 | 0.97 | CA2 (0.58) | CA2FAAHCES1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312337-B2 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY (US) | 2007-12-25 | — | — | US | claimed |
| US-7268235-B2 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY (US) | 2007-09-11 | — | — | US | claimed |
| US-20060074245-A1 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY | 2006-04-06 | — | — | US | claimed |
| US-20060069262-A1 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY | 2006-03-30 | — | — | US | claimed |
| US-6657083-B2 | Photographic couplers; acylation amine group in position 2 | EASTMAN KODAK COMPANY | 2003-12-02 | — | — | US | claimed |
| US-6613943-B2 | Intermediates for 4-substituted-2,5-diaminophenol derivatives as phenolic cyan couplers for color photography; deblocking the 2-acyl group by hydrolysis | EASTMAN KODAK COMPANY | 2003-09-02 | — | — | US | claimed |
| US-20030109716-A1 | 5-ACYLAMINO-2-AMINO-4-SUBSTITUTED-PHENOL COMPOUNDS AND METHOD OF USING THEM | EASTMAN KODAK COMPANY | 2003-06-12 | — | — | US | claimed |
| US-20030109753-A1 | 4-acylamino-2-hydroxy-5-substituted-acylanilide compounds and method of using them | EASTMAN KODAK COMPANY | 2003-06-12 | — | — | US | claimed |
| US-6525219-B1 | Chemical intermediates for cyan dye forming couplers; deblocking, hydrolysis, acylation | EASTMAN KODAK COMPANY | 2003-02-25 | — | — | US | claimed |
| US-6476202-B1 | 5-acylamino-2-arylazo, nitro, or nitroso-4-substituted-phenol compounds and method of using them | EASTMAN KODAK COMPANY | 2002-11-05 | — | — | US | claimed |
| US-7312337-B2 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7268235-B2 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY (US) | 2007-09-11 | — | — | US | disclosed |
| US-20060074245-A1 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY | 2006-04-06 | — | — | US | disclosed |
| US-20060069262-A1 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY | 2006-03-30 | — | — | US | disclosed |
| US-6657083-B2 | Photographic couplers; acylation amine group in position 2 | EASTMAN KODAK COMPANY | 2003-12-02 | — | — | US | disclosed |
| EP-1316550-A1 | 6-Acylamino-5-substituted-benzoxazol-2-one compounds and method for using them | EASTMAN KODAK COMPANY (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6525219-B1 | Chemical intermediates for cyan dye forming couplers; deblocking, hydrolysis, acylation | EASTMAN KODAK COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6515176-B1 | Disclosed is a 6-acylamino-5-substituted-benzoxazol-2-one compound having the structural formula I: Also disclosed is a method for forming a cyan dye-forming coupler from the above compound. The method and intermediate with a simplified | EASTMAN KODAK COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-6482953-B1 | 2-benzyloxy-4-nitro-5-substituted-acylanilide compounds and method of using them | EASTMAN KODAK COMPANY | 2002-11-19 | — | — | US | disclosed |
| US-6482985-B1 | 2-benzyloxy-5-halo-acylanilide compounds and method of using them | EASTMAN KODAK COMPANY | 2002-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109753-A1 | 4-acylamino-2-hydroxy-5-substituted-acylanilide compounds and method of using them | CBR3, AADAC, HAAO | CA2 1033/4885FAAH 152/4885CES1 1874/4885 |
| US-20030109716-A1 | 5-ACYLAMINO-2-AMINO-4-SUBSTITUTED-PHENOL COMPOUNDS AND METHOD OF USING THEM | AADAT, AAAS, ANXA7 | CA2 1481/4885FAAH 1756/4885CES1 4394/4885 |
| US-20060069262-A1 | Oxadiazoles and their manufacture | OXA1L, CYP1B1, OXER1 | CA2 4256/4885FAAH 4161/4885CES1 1501/4885 |
| US-20060074245-A1 | Method for preparation of N-pyrazolylamidoximes | KCNH1, KCNJ2, KCNH2 | CA2 2804/4885FAAH 1277/4885CES1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.